
Piotr Cywoniuk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8055997/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mechanistic determinants of MBNL activity. Nucleic Acids Research, 2016, 44, gkw915.	6.5	56
2	MBNL1 alternative splicing isoforms play opposing roles in cancer. Life Science Alliance, 2018, 1, e201800157.	1.3	41
3	MBNL splicing activity depends on RNA binding site structural context. Nucleic Acids Research, 2018, 46, 9119-9133.	6.5	28
4	Novel Strategies in Artificial Organ Development: What Is the Future of Medicine?. Micromachines, 2020, 11, 646.	1.4	21
5	Bionic Organs: Shear Forces Reduce Pancreatic Islet and Mammalian Cell Viability during the Process of 3D Bioprinting. Micromachines, 2021, 12, 304.	1.4	19
6	AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1. Nucleic Acids Research, 2020, 48, 2531-2543.	6.5	12
7	Hybrid splicing minigene and antisense oligonucleotides as efficient tools to determine functional protein/RNA interactions. Scientific Reports, 2017, 7, 17587.	1.6	11
8	Stem Cells as a Source of Pancreatic Cells for Production of 3D Bioprinted Bionic Pancreas in the Treatment of Type 1 Diabetes. Cells, 2021, 10, 1544.	1.8	11
9	The Influence of the Flow of Detergent and Donor Characteristics on the Extracellular Matrix Composition After Human Pancreas Decellularization. Transplantation Proceedings, 2020, 52, 2043-2049.	0.3	7
10	Application of ion pair chromatography coupled with mass spectrometry to assess antisense oligonucleotides concentrations in living cells. Analyst, The, 2019, 144, 622-633.	1.7	6
11	Crosstalk Between Immunity System Cells and Pancreas. Transformation of Stem Cells Used in the 3D Bioprinting Process as a Personalized Treatment Method for Type 1 Diabetes. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 13.	1.0	3